Biopharma needs value focused commercial model, says Quintiles

By Gareth Macdonald and Claire Videau

- Last updated on GMT

Addressing the drug industry's need to demonstrate value to stakeholders presents a significant opportunity for service providers, according to Jim Featherstone, VP of Quintiles' commercial arm.

Dr Featherstone spoke with Outsourcing-pharma about some of the challenges of commercialising a new drug product in a rapidly evolving pharmaceutical market where approval is the end of the beginning rather than the ultimate goal.

Part of the problem, he suggested, is that biopharma firms need a new value-focused model where communication with patients, payers and regulators at the earliest possible stage in the development process takes centre stage.

This type of communication is a significant market for the contract services sector according to Featherstone, who suggested that drugmakers often lack the in-house knowhow and expertise to undertake such projects.

Related news

Show more

Related products

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers